Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant

Eunice L. Kwak, Sang Kim, Jianmin Zhang, Robert Cardiff, Emmett V. Schmidt, Daniel A. Haber

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


A truncating allele of the cell cycle checkpoint kinase CHK2 is present in 1% of the population, conferring a moderate increase in breast cancer risk, and inactivation of chk2 enhances mammary tumorigenesis in mice with targeted inactivation of brca1. We used the mouse mammary tumor virus (MMTV) promoter to target expression of a kinase-dead CHK2 allele (D347A). Mammary tumors, of predominantly micropapillary histology, developed in 40% of MMTV-CHK2-D347A transgenic mice with an average latency of 20 months. Tumors metastasized to lung and spleen; tumor-derived cell lines were frequently aneuploid and showed suppression of irradiation-induced p53 function. Primary hematopoietic malignancies were also observed in the spleen, another site of MMTV expression. The increased rate of tumor formation in MMTV-CHK2-D347A mice, compared with the relatively low incidence in chk2-null mice, provides a model to study modifiers of CHK2-dependent transformation.

Original languageEnglish (US)
Pages (from-to)1923-1928
Number of pages6
JournalCancer Research
Issue number4
StatePublished - Feb 15 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant'. Together they form a unique fingerprint.

Cite this